Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Intellia Therapeutics Inc (NASDAQ: NTLA) was $16.11 for the day, up 29.81% from the previous closing price of $12.41. In other words, the price has increased by $29.81 from its previous closing price. On the day, 16.44 million shares were traded. NTLA stock price reached its highest trading level at $16.38 during the session, while it also had its lowest trading level at $13.0.
Ratios:
Our analysis of NTLA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.19 and its Current Ratio is at 5.19. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.11.
On March 05, 2025, H.C. Wainwright started tracking. The Stock assigning a Buy rating and target price of $30. JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for. The Stock was revised from $45 to $13.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 20 ’25 when CHASE WILLIAM J bought 100,000 shares for $10.03 per share. The transaction valued at 1,003,000 led to the insider holds 134,693 shares of the business.
Dulac Edward J III sold 7,462 shares of NTLA for $104,617 on Jul 23 ’25. The EVP, Chief Financial Officer now owns 106,062 shares after completing the transaction at $14.02 per share. On Jul 01 ’25, another insider, Clark Eliana, who serves as the EVP, Chief Technical Officer of the company, sold 1,022 shares for $9.82 each. As a result, the insider received 10,036 and left with 95,369 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1729358464 and an Enterprise Value of 1372298368. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 32.72 while its Price-to-Book (P/B) ratio in mrq is 2.37. Its current Enterprise Value per Revenue stands at 25.962 whereas that against EBITDA is -2.734.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.30, which has changed by -0.26371115 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $23.76, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of. The Stock is 36.85%, while the 200-Day Moving Average is calculated to be 56.30%.
Shares Statistics:
NTLA traded an average of 4.62M shares per day over the past three months and 6315680 shares per day over the past ten days. A total of 105.33M shares are outstanding, with a floating share count of 101.11M. Insiders hold about 5.81% of the company’s shares, while institutions hold 87.85% stake in the company. Shares short for NTLA as of 1756425600 were 27737890 with a Short Ratio of 6.01, compared to 1753920000 on 29708601. Therefore, it implies a Short% of Shares Outstanding of 27737890 and a Short% of Float of 29.270000000000003.
Earnings Estimates
At present, 21.0 analysts are actively evaluating the performance of Intellia Therapeutics Inc (NTLA) in. The Stock market.The consensus estimate for the next quarter is -$0.97, with high estimates of $0.04 and low estimates of -$1.49.
Analysts are recommending an EPS of between -$2.67 and -$4.74 for the fiscal current year, implying an average EPS of -$4.08. EPS for the following year is -$3.97, with 24.0 analysts recommending between -$2.37 and -$5.05.
Revenue Estimates
A total of 25 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $30.87M, resulting in an average revenue estimate of $61.75M. In the same quarter a year ago, actual revenue was $57.88M
